Company intelligence / Profile preview

OncoRev

Baltimore, Maryland, United States

Ownership: Private
Development stage: Other

Overview

OncoRev is a preclinical-stage biotechnology company focused on developing small molecule inhibitors to overcome chemoresistance in cancer. The company's primary technology targets the translesion synthesis (TLS) pathway, specifically the interaction between REV1 and REV7 proteins, which allows cancer cells to bypass DNA damage caused by chemotherapy. By inhibiting this pathway, OncoRev aims to sensitize resistant tumors to standard-of-care treatments like cisplatin and carboplatin. The company was founded based on research from the University of Maryland School of Medicine and operates out of the University of Maryland BioPark. Its approach represents a novel strategy to restore the effectiveness of existing oncology treatments in patients with refractory disease.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on OncoRev.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OncoRev.

Explore the full profile